Related Experiment Video
Updated: Apr 19, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
Detection of kinase amplifications in gastric adenocarcinomas
Muhsin Özdemiri1, Murat Öznur, Evrim Çiftçi
1Department of Medical Genetics, Eskişehir Osmangazi University, Eskişehir, Turkey. mozdemir@ogu.edu.tr
Aim:
To determine the incidences of copy number aberrations of receptor kinases and their relations in Turkish patients with gastric adenocarcinoma.
Materials And Methods:
The prevalence of genomic copy number aberrations of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2)/topoisomerase IIa (TOP2A), centrosome-associated kinase aurora A (AURK A), centrosome-associated kinase aurora B (AURK B), and mesenchymal-epithelial transition factor (MET) genes and polysomies of related chromosomes were analyzed by fluorescent in situ hybridization (FISH) in tumor samples from 35 patients with gastric cancer.
Results:
There were 28.6%, 65.7%, 20.0%, 17.1%, 60.0%, and 45.7% cases considered FISH-positive for EGFR, MET, HER2, TOP2A, AURK A, and AURK B genes, respectively. Statistically significant associations were determined in detection of amplifications of 1) EGFR gene with chromosome 7 polysomy, 2) MET gene in nonpolysomic chromosome 7 nuclei, 3) HER2/TOP2A genes in nonpolysomic chromosome 17 nuclei, 4) coamplification of HER2/TOP2A in poorly differentiated carcinomas, and 5) AURK A gene in nonpolysomic chromosome 20 nuclei. Most of the aberrations were predominantly seen in poorly differentiated tumors, but a high rate of the amplified MET gene was also detected in moderately differentiated carcinomas.
Conclusion:
Chromosome 7 polysomy may be responsible for EGFR gene amplifications, and we concluded that MET and AURK A genes amplifications were commonly seen aberrations in gastric adenocarcinomas and may offer information about disease progression and administration of individualized treatment for gastric cancer patients.
Insights
Copy number aberrations in receptor kinases like MET and AURK A are common in gastric adenocarcinoma. These genetic changes, particularly MET and AURK A amplifications, may indicate disease progression and guide personalized gastric cancer treatment.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Gastric adenocarcinoma is a significant global health concern.
- Understanding the genetic landscape of gastric cancer is crucial for developing targeted therapies.
- Receptor kinases play vital roles in cell signaling and cancer development.
Purpose of the Study:
- To investigate the frequency of copy number aberrations in key receptor kinase genes.
- To explore the relationship between these aberrations and clinicopathological features in Turkish gastric cancer patients.
- To identify potential biomarkers for disease progression and treatment strategies.
Main Methods:
- Fluorescent in situ hybridization (FISH) was used to analyze copy number variations.
- Tumor samples from 35 Turkish gastric cancer patients were examined.
- Genes analyzed included EGFR, HER2/TOP2A, AURK A, AURK B, and MET, along with related chromosome polysomies.
Main Results:
- High incidences of FISH-positive cases were observed for MET (65.7%) and AURK A (60.0%).
- Significant associations were found between EGFR amplification and chromosome 7 polysomy.
- MET and AURK A gene amplifications were frequently detected, particularly in poorly differentiated tumors.
Conclusions:
- Chromosome 7 polysomy may drive EGFR amplification in gastric cancer.
- MET and AURK A gene amplifications are common in gastric adenocarcinomas.
- These aberrations may serve as indicators of disease progression and inform individualized treatment approaches.
More Related Videos
09:49Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
Published on: July 5, 2019
09:16Detection of a CDH1 Rare Transcript Variant in Fresh-frozen Gastric Cancer Tissues by Chip-based Digital PCR
Published on: February 5, 2018
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Amplifying Signals via Enzymatic Cascade